Cargando…
Intravesical Injection of Abobotulinumtoxin-A in Patients with Bladder Pain Syndrome/Interstitial Cystitis
OBJECTIVE: This study aimed to evaluate retrospectively the outcomes of Abobotulinumtoxin-A (Dysport®) intravesical injection in refractory interstitial cystitis/bladder pain syndrome patients to first- and second-line treatment. MATERIALS AND METHODS: From March 2016 to 2021, 44 adult patients with...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Turkish Association of Urology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346116/ https://www.ncbi.nlm.nih.gov/pubmed/37877871 http://dx.doi.org/10.5152/tud.2023.22243 |
_version_ | 1785073238801383424 |
---|---|
author | Rahnama’i, Mohammad-Sajjad Salehi-Pourmehr, Hanieh Saeedi, Sana Tayebi, Sona Hajebrahimi, Sakineh |
author_facet | Rahnama’i, Mohammad-Sajjad Salehi-Pourmehr, Hanieh Saeedi, Sana Tayebi, Sona Hajebrahimi, Sakineh |
author_sort | Rahnama’i, Mohammad-Sajjad |
collection | PubMed |
description | OBJECTIVE: This study aimed to evaluate retrospectively the outcomes of Abobotulinumtoxin-A (Dysport®) intravesical injection in refractory interstitial cystitis/bladder pain syndrome patients to first- and second-line treatment. MATERIALS AND METHODS: From March 2016 to 2021, 44 adult patients with bladder pain syndrome who were refractory to first- and second-line treatment were enrolled in our study. The Bladder Pain/Interstitial Cystitis Symptom Score questionnaire was filled out for every patient before and 1-3 months after intervention in addition to urodynamic evaluation. Patient satisfaction was evaluated using a scoring system that was defined as high or >80% improvement (highly satisfied), intermediate 40%-79% (intermediate satisfaction), and poor 0%-39% improvement. RESULTS: The mean age of our study population was 57 years, including 41 females and 3 males. The mean follow-up time was 9 months. According to the results of urodynamics, 68% of cases had low capacity, and detrusor overactivity, while 18% had only low capacity. In terms of the endpoint outcome, half of the patients (52%) had intermediate satisfaction, whereas 41% reported a good response. Only 3 cases had no response or felt (7%) any improvement after the intervention (poor response). The paired t-test analysis revealed that the mean Bladder Pain/Interstitial Cystitis Symptom Score was reduced after injection (P = .001). CONCLUSION: Our results showed the efficacy and safety of intravesical injections with Abobotulinumtoxin-A (Dysport®) in patients with interstitial cystitis/bladder pain syndrome. Further randomized controlled trials are recommended to investigate its superiority over placebo considering the need for anesthesia, the occurrence of local complications, risks of urinary retention, and a large post-void residual (PVR) volume. |
format | Online Article Text |
id | pubmed-10346116 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Turkish Association of Urology |
record_format | MEDLINE/PubMed |
spelling | pubmed-103461162023-07-15 Intravesical Injection of Abobotulinumtoxin-A in Patients with Bladder Pain Syndrome/Interstitial Cystitis Rahnama’i, Mohammad-Sajjad Salehi-Pourmehr, Hanieh Saeedi, Sana Tayebi, Sona Hajebrahimi, Sakineh Urol Res Pract Original Article OBJECTIVE: This study aimed to evaluate retrospectively the outcomes of Abobotulinumtoxin-A (Dysport®) intravesical injection in refractory interstitial cystitis/bladder pain syndrome patients to first- and second-line treatment. MATERIALS AND METHODS: From March 2016 to 2021, 44 adult patients with bladder pain syndrome who were refractory to first- and second-line treatment were enrolled in our study. The Bladder Pain/Interstitial Cystitis Symptom Score questionnaire was filled out for every patient before and 1-3 months after intervention in addition to urodynamic evaluation. Patient satisfaction was evaluated using a scoring system that was defined as high or >80% improvement (highly satisfied), intermediate 40%-79% (intermediate satisfaction), and poor 0%-39% improvement. RESULTS: The mean age of our study population was 57 years, including 41 females and 3 males. The mean follow-up time was 9 months. According to the results of urodynamics, 68% of cases had low capacity, and detrusor overactivity, while 18% had only low capacity. In terms of the endpoint outcome, half of the patients (52%) had intermediate satisfaction, whereas 41% reported a good response. Only 3 cases had no response or felt (7%) any improvement after the intervention (poor response). The paired t-test analysis revealed that the mean Bladder Pain/Interstitial Cystitis Symptom Score was reduced after injection (P = .001). CONCLUSION: Our results showed the efficacy and safety of intravesical injections with Abobotulinumtoxin-A (Dysport®) in patients with interstitial cystitis/bladder pain syndrome. Further randomized controlled trials are recommended to investigate its superiority over placebo considering the need for anesthesia, the occurrence of local complications, risks of urinary retention, and a large post-void residual (PVR) volume. Turkish Association of Urology 2023-05-01 /pmc/articles/PMC10346116/ /pubmed/37877871 http://dx.doi.org/10.5152/tud.2023.22243 Text en © 2023 authors https://creativecommons.org/licenses/by/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Original Article Rahnama’i, Mohammad-Sajjad Salehi-Pourmehr, Hanieh Saeedi, Sana Tayebi, Sona Hajebrahimi, Sakineh Intravesical Injection of Abobotulinumtoxin-A in Patients with Bladder Pain Syndrome/Interstitial Cystitis |
title | Intravesical Injection of Abobotulinumtoxin-A in Patients with Bladder Pain Syndrome/Interstitial Cystitis |
title_full | Intravesical Injection of Abobotulinumtoxin-A in Patients with Bladder Pain Syndrome/Interstitial Cystitis |
title_fullStr | Intravesical Injection of Abobotulinumtoxin-A in Patients with Bladder Pain Syndrome/Interstitial Cystitis |
title_full_unstemmed | Intravesical Injection of Abobotulinumtoxin-A in Patients with Bladder Pain Syndrome/Interstitial Cystitis |
title_short | Intravesical Injection of Abobotulinumtoxin-A in Patients with Bladder Pain Syndrome/Interstitial Cystitis |
title_sort | intravesical injection of abobotulinumtoxin-a in patients with bladder pain syndrome/interstitial cystitis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346116/ https://www.ncbi.nlm.nih.gov/pubmed/37877871 http://dx.doi.org/10.5152/tud.2023.22243 |
work_keys_str_mv | AT rahnamaimohammadsajjad intravesicalinjectionofabobotulinumtoxinainpatientswithbladderpainsyndromeinterstitialcystitis AT salehipourmehrhanieh intravesicalinjectionofabobotulinumtoxinainpatientswithbladderpainsyndromeinterstitialcystitis AT saeedisana intravesicalinjectionofabobotulinumtoxinainpatientswithbladderpainsyndromeinterstitialcystitis AT tayebisona intravesicalinjectionofabobotulinumtoxinainpatientswithbladderpainsyndromeinterstitialcystitis AT hajebrahimisakineh intravesicalinjectionofabobotulinumtoxinainpatientswithbladderpainsyndromeinterstitialcystitis |